Getinge Ab Class B · OMXSTO:GETI_B
Getinge Ab Class B — Q3 2026 Earnings Presentation
17 slides from Getinge Ab Class B's earnings presentation, Oct 21, 2026
Slide 1: Increased profitability, strong cash flow and higher customer satisfaction
Increased profitability, strong cash flow and higher customer satisfaction Getinge Q3 2026 Mattias Perjos, CEO Agneta Palmér, CFO
Slide 2: Key pillars for Getinge's profitable growth journey
Key pillars for Getinge’s profitable growth journey Development for strategic KPIs Increase share from recurring revenue Increase sales share from high margin products1 Less field actions per Bn SEK Net sales Capital goods Recurring revenue Rest of Portfolio High margin products -42% 1,9 1,2 1,1 1,0
Slide 3: Key takeaways
Key takeaways Q3 2026 • Net sales grew by 2.1% organically and order intake increased by 2.6% organically • Healthy margins in the quarter – primarily from solid underlying improvement in the business • Strong cash flow and financial position 38,000 53 16 15.6 51.8 36,000 34,455 52 15 34,000 51 0 0
Slide 4: Key activities and events
Key activities and events Q3 2026 Offering and Customers Sustainability, Quality and other • All-time high in annual customer satisfaction survey • 510(k) clearance for new Edi catheter designed for premature infants weighing between 500 and 1000 grams • Cardiohelp II successfully launched in CE cou
Slide 5: Organic topline growth – driven by ACT and SW
Organic topline growth – driven by ACT and SW Order Intake and Net Sales Bridge Q3 2025 – Q3 2026 Order Intake Net Sales Organic Organic change +2.4% -1.4% +4.5% +2.6% change +4.5% -3.6% +0.7% +2.1% +3.6% 187 +2.7% 126 177 75 -8 -31 8,477 8,781 8,226 8,446 SEK M SEK M Q3 2025 Acute Care Life Surgica
Slide 6: Margins strengthened by underlying improvements and tariff refund
Margins strengthened by underlying improvements and tariff refund Adjusted Gross Profit and EBITA Bridge Q3 2025 – Q3 2026 Adjusted Gross Profit Adjusted EBITA Adj GM,% Margin development Q3 2026 59.6 38.4 43.5 51.4 +1.7 pp Adj GP (Q3 2025) (56.6) (36.5) (42.8) (49.2) +0.1 pp Adj OPEX +0.0 pp D&A +7
Slide 7: Getinge continues to have a solid financial position
Getinge continues to have a solid financial position Strong FCF in quarter and good safety margin on leverage FCF positively impacted by improved operating profit… … and leverage continues to be well below 2.5x 1.6 1.7 1.5 1.5 1.5 1.3 1.2 1.0 1.7 1.6 1.5 1.5 1.5 0.8 0.8 (1.1x excl. pension liabiliti
Slide 8: Steady traction towards mid-term guidance span
Steady traction towards mid-term guidance span Closing in on the span of 16-19%* R12 Adj. EBITA margin 19 18 Mid-term guidance span of 16-19% adj. EBITA by end of 2028 17 +3.6 pp 16 15.8 15.0 15.6 15 Key levers: ∆ Significant quality cost release, gradually from H2 2026 to 2028 14 14.0 ∆ Mix shift t
Slide 9: Net sales for 2026 expected to increase by 3-5% organically
Outlook 2026 Net sales for 2026 expected to increase by 3-5% organically* * Adjusted for the phase-out of Surgical Perfusion, which is expected to have net sales in 2026 declining from about 250 MSEK to 50 MSEK Getinge │ Presentation │ Q3 Report 2026 October 21, 2026 Page 9
Slide 10: Summary
Summary Getinge │ Presentation │ Q3 Report 2026 October 21, 2026 Page 10
Slide 11: Key takeaways
Key takeaways Summary Q3 2026 • Net sales grew by 2.1% organically and order intake increased by 2.6% organically • Healthy margins in the quarter – primarily impacted by solid underlying improvement • Strong cash flow and financial position • Outlook for 2026: organic net sales growth of 3-5%, adju
Slide 12: Q&A
Q&A Getinge │ Presentation │ Q3 Report 2026 October 21, 2026 Page 12
Slide 13: Appendix – Equity story
Appendix – Equity story Getinge │ Presentation │ Q3 Report 2026 October 21, 2026 Page 13
Slide 14: World-leading Medtech at an inflection point
World-leading Medtech at an inflection point Quality cost release beginning H2 2026, the operational inflection is visible WHO WE ARE INVESTMENT CASE SHAREHOLDER RETURN #1-2 positions in core categories Visible margin recovery Prioritised dividend and healthy leverage Underlying improvement masked i
Slide 15: Thank you
Thank you Getinge │ Presentation │ Q3 Report 2026 October 21, 2026 Page 15
Slide 16: Forward-looking information
Forward-looking information This document contains forward-looking information based on the current expectations of Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations wi
Slide 17: Getinge
“~~ Se A GETINGE PASSION FOR LIFE